AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.87 |
Market Cap | 77.25M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.07 |
PE Ratio (ttm) | -0.91 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.89 |
Volume | 82,347 |
Avg. Volume (20D) | 240,950 |
Open | 1.82 |
Previous Close | 1.78 |
Day's Range | 1.80 - 1.95 |
52-Week Range | 1.49 - 6.06 |
Beta | undefined |
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...
Analyst Forecast
According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 931.86% from the latest price.